AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HAE · NYSE · Medical - Devices

Haemonetics (HAE)

Blood-collection platforms and hospital devices for transfusion, surgery, and cardiac procedures.

$108.52

After hours−0.03 (−0.03%)

At close$108.55(−0.17%)

In millions of USD, except per-share figures

In millions	Q2 FY24Sep 2023	Q3 FY24Dec 2023	Q4 FY24Mar 2024	Q1 FY25Jun 2024	Q2 FY25Sep 2024	Q3 FY25Dec 2024	Q4 FY25Mar 2025	Q1 FY26Jun 2025	Q2 FY26Sep 2025	Q3 FY26Dec 2025	Q4 FY26Mar 2026	Q1 FY27Jun 2026
Revenue	318	336	343	336	346	349	331	321	327	339	346	339
Cost of revenue	148	151	154	157	154	149	149	130	144	148	148	137
Gross profit	171	185	189	179	191	200	182	192	183	191	198	203
	135	139	159	140	140	141	130	138	116	122	147	145
Research & development	13	13	24	14	14	16	16	16	15	14	14	16
	0	0	115	0	0	0	115	0	102	108	122	119
Selling & marketing	0	0	7	0	0	0	0	0	0	0	0	0
General & administrative	0	0	108	0	0	0	0	0	0	0	0	119
Other expenses	123	126	19	125	125	125	0	122	0	0	10	10
Operating income	35	46	30	40	52	59	51	54	67	70	51	57
	−2	−2	−7	7	−7	−9	19	−9	−16	−10	−80	−10
Interest income	0	0	0	7	0	0	1	0	0	0	0	0
Interest expense	2	2	7	0	7	9	0	4	7	8	5	10
Other non-operating income	−7	−13	−19	−11	−8	−7	−19	−11	9	1	74	10
Income before tax	33	44	23	47	45	50	71	45	51	60	−28	48
Income tax expense	8	13	3	8	11	12	13	11	13	15	−8	15
Net income from continuing operations	25	31	20	38	34	37	58	34	39	45	−20	33
Net income	25	31	20	38	34	37	58	34	39	45	−20	33
EPS, basic	$0.49	$0.62	$0.40	$0.75	$0.66	$0.75	$1.17	$0.71	$0.81	$0.96	−$0.44	$0.73
EPS, diluted	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74	$1.17	$0.70	$0.81	$0.95	−$0.44	$0.72
Weighted average shares, basic	51	51	51	51	51	50	49	48	48	47	46	45
Weighted average shares, diluted	51	51	51	52	51	51	49	48	48	47	46	46
EBITDA	66	83	68	80	89	95	99	94	87	95	4	75
Depreciation & amortization	23	24	19	29	29	29	28	29	28	27	27	27
EBIT	43	59	49	51	60	66	71	65	58	68	−23	48